Joflam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Joflam

What is Joflam?

Joflam is a pharmaceutical medication categorized as a non-steroidal anti-inflammatory drug (NSAID). It contains the active ingredient diclofenac, specifically in the form of diclofenac potassium. This formulation is designed to be absorbed relatively quickly by the body compared to other forms of the compound.

Mechanism of Action

The medication works by inhibiting the activity of enzymes known as cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). These enzymes play a central role in the production of prostaglandins, which are lipid compounds that act as chemical messengers in the body. Prostaglandins are responsible for signaling pain, inducing inflammation, and triggering fever responses. By reducing the concentration of these compounds, the medication helps manage symptoms associated with various inflammatory conditions.

Therapeutic Use

Joflam is primarily utilized to address acute and chronic symptoms related to inflammation and pain. Because it targets the underlying chemical triggers of discomfort, it is often used in the management of:

  • Arthritic conditions: Including rheumatoid arthritis and osteoarthritis, where joint inflammation causes stiffness and pain.
  • Acute musculoskeletal injuries: Such as sprains, strains, and back pain.
  • Post-operative recovery: To manage inflammation following surgical procedures.
  • Menstrual discomfort: To alleviate painful cramping.

Physical Characteristics

As diclofenac potassium, the medication is typically presented in an immediate-release tablet format. This allows the active substance to enter the bloodstream efficiently, making it suitable for conditions where rapid relief from pain and swelling is required.

What side effects are possible with Joflam?

The possible side effects and safety profile of Joflam (Diclofenac) are formally documented in regulatory labeling according to system-organ class and frequency of occurrence.

Adverse Reaction Scope

Category Description based on Regulatory Documentation
Key adverse reaction categories Gastrointestinal (GI), Cardiovascular, Nervous System, Hepatobiliary, Renal, and Skin reactions, which are recognized adverse effects for the nonsteroidal anti-inflammatory drug (NSAID) class.
Common effects Gastrointestinal symptoms such as dyspepsia, nausea, abdominal pain, diarrhea, and flatulence, along with nervous system effects like headache and dizziness, are commonly documented.
Serious adverse reactions The labeling highlights severe risks, including Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and life-threatening Gastrointestinal Bleeding, Ulceration, and Perforation. Rare but severe Hepatotoxicity (liver failure) and serious Skin Adverse Reactions (e.g., Stevens-Johnson Syndrome) are also noted.
Population-specific considerations Older adults have a higher risk for serious GI events. Diclofenac is contraindicated for pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery and must be avoided starting at 30 weeks gestation in pregnancy due to risks to the fetus.
Duration-related patterns Cardiovascular risk may occur early in treatment and increase with the duration of use. Serious GI events can occur at any time and often without warning symptoms.

Regulatory Safety Summary

The safety profile is formally classified by System-Organ-Class, detailing documented effects on the gastrointestinal, cardiovascular, nervous, and renal systems. Serious Adverse Reactions are designated as critical risks in official labeling. Risk is explicitly linked to duration of use, and specific constraints apply to older adults and the late stages of pregnancy as defined by regulatory bodies.

This documentation ensures that potential adverse events are formally categorized and communicated, highlighting the critical safety areas for this pharmacological class.

Overdose and Emergency Response

Overdose and when to seek help

In the event of a suspected over-ingestion of Joflam, regulatory authorities mandate that you seek immediate medical attention by contacting emergency services or a Poison Control Center without delay.

Documented Overdose Presentations and Risks

Acute overdose may present with a cluster of documented clinical manifestations. Common signs include gastrointestinal disturbances such as nausea, vomiting (sometimes with blood), stomach pain, and diarrhea, alongside Central Nervous System (CNS) effects like headache, dizziness, drowsiness, confusion, and ringing in the ears.

A severe over-ingestion carries the risk of serious, life-threatening outcomes, including acute renal failure, liver damage, and gastrointestinal bleeding or perforation, which can be fatal. Severe CNS manifestations such as seizures or coma have also been officially documented. The risk of serious gastrointestinal events is higher in elderly patients, and those with pre-existing renal or hepatic impairment are more susceptible to severe toxicity.

Management and Emergency Procedures

Official labeling states that management for Diclofenac toxicity is symptomatic and supportive, as no specific antidote is known. Hospital monitoring of vital signs and key organ functions (renal, hepatic) is typically required to manage potential complications. Procedures such as the administration of activated charcoal may be employed within the first hour of ingestion in certain cases.

Therapeutic Uses of Joflam

What Joflam Treats: Main Uses and Benefits

Joflam generally helps with symptoms related to physical discomfort and inflammatory or irritative states. As an established non-steroidal anti-inflammatory drug (NSAID), Joflam is applied across domains where additional symptomatic support is needed. It may assist with easing symptoms that create noticeable functional strain.

This medication is considered relevant for easing symptoms related to heightened physiological activity, such as pain (including headaches, muscle aches, and joint discomfort), localized swelling and tenderness, and fever. It is applicable in conditions characterized by periods of heightened symptoms, including managing discomfort from minor strains, sprains, or painful menstrual periods. Joflam may provide support that helps ease the overall symptom burden during symptomatic phases.

Quick Fact: Focus on Symptomatic Relief Joflam is applied in addressing symptom clusters that may become intense or disruptive in situations involving inflammatory or irritative states.

“The easing of swelling may contribute to improved day-to-day comfort and may assist with maintaining functional stability.”

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac

Eligibility and Restrictions for Use

Joflam, which contains the active substance diclofenac (a non-steroidal anti-inflammatory drug or NSAID), is typically prescribed to adults for short-term relief of pain and inflammation, such as in cases of sprains, strains, or post-operative pain. Dosage for adolescents (age 14 and over) must be determined by a healthcare provider.

However, Joflam is not suitable for all patients. It is contraindicated in several circumstances due to the potential for serious adverse effects. You must not take this medicine if any of the following apply to you:

Condition
A known allergy to diclofenac, aspirin, ibuprofen, or any other NSAID
Active stomach or intestinal ulceration or bleeding, or a history of recurrent gastrointestinal bleeding
Severe kidney or liver disease
Severe heart failure (NYHA class II–IV)
Established ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease (such as a history of heart attack or stroke)
The last three months of pregnancy

Additionally, Joflam is generally not recommended for children under 14 years of age or for women who are breastfeeding. Consult your doctor immediately to discuss alternative treatments if you have existing conditions like mild-to-moderate heart failure, high blood pressure, diabetes, or other risk factors for cardiovascular events, as these require careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Joflam (Diclofenac) has documented interaction patterns that are classified according to their official regulatory outcome, primarily impacting clearance and pharmacodynamic risk. Co-administration with other systemic NSAIDs, including COX-2 selective inhibitors, is formally not recommended due to an additive risk of serious gastrointestinal events. Diclofenac is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Pharmacokinetic Constraints

Interactions with Anticoagulants (e.g., Warfarin), Antiplatelet Agents (e.g., Aspirin), and SSRIs/SNRIs carry an increased risk of serious bleeding as a primary pharmacodynamic effect. Diclofenac affects drug clearance by increasing the serum concentrations of co-administered medicines like Lithium and Digoxin, and increasing the toxicity of Methotrexate due to impaired renal excretion.

Metabolic interactions are documented where the inhibitor Voriconazole causes an increase in Diclofenac plasma concentration (AUC/Cmax). Conversely, the drug may diminish the antihypertensive effect of ACE Inhibitors/ARBs and the natriuretic effect of Diuretics.

For Methotrexate, administration carries an increased risk of toxicity when given within 24 hours of Diclofenac. The official label advises that co-administration of Alcohol may increase the risk of serious gastrointestinal problems.

Mechanism of Action

Molecular Mechanism: Inhibition of COX Enzymes

The active molecule acts as an enzyme inhibitor, blocking the activity of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This fundamental action prevents the initial molecular step where the target molecules process arachidonic acid into various signaling lipids. This step initiates the mechanistic cascade by interfering with the entire downstream signaling sequence.


Pathway Effect: Modulation of Lipid Mediators

The inhibition of the COX enzymes directly restricts the generation of eicosanoid mediators, most notably prostaglandins ( PGE2). These mediators function to amplify signals of nociception (pain signaling) and regulate local thermal responses. By limiting their production, the molecule modulates pathways associated with heightened physiological responses, resulting in a systemic restriction of inflammatory signal amplification and an alteration of the thermoregulatory set-point in the central nervous system.


Systemic Consequence: Modulation of Sensory Signaling

The mechanism operates in both peripheral and central biological systems, influencing sensory signaling pathways. Reduced prostaglandin synthesis near nerve endings alters the excitability threshold of nociceptors (pain-sensing neurons). This alteration in the local chemical environment results in a change in the frequency of signal transmission by sensory neurons, thereby modulating the central perception of nociceptive input.

Dosage and Administration Information

How to Use Joflam

Joflam (Diclofenac) is administered according to a protocol that dictates the route, dosage, frequency, and duration of use, based on the specific formulation. The overarching principle across all forms is to utilize the lowest effective dose for the shortest duration possible to manage symptoms.


Official Routes and Administration Patterns

Joflam is authorized for several administration routes, including oral (tablets, capsules, solution powder), topical (gel, solution), and parenteral (intravenous or intramuscular injection).

Administration Type Dosing Schedule Principle Administration Contexts
Oral (Systemic) Maximum daily dose is generally 150 mg in divided doses, or 100 mg once daily for extended-release forms. Oral powder must be mixed with water only and taken on an empty stomach. Delayed-release tablets must not be crushed or chewed.
Topical (Local) Measured application of 2 g or 4 g up to four times daily to the affected area. Application requires the use of a dosing card for accurate measurement. The treated area should not be washed or covered with an occlusive dressing for a specified period.
Parenteral (Acute) 37.5 mg every 6 hours, not exceeding 150 mg daily. Intended only for short-term use (e.g., IM for no more than two days). Patients must be well hydrated before IV injection to reduce risk.

Duration and Special Use Constraints

Instructions place limits on treatment duration; for instance, injectable forms are restricted to acute, short-term management. For older adults, labeling recommends using the lowest possible effective dose. If a dose is missed, guidance advises skipping the missed dose and continuing with the normal schedule; do not take a double dose to compensate.

Recent Clinical Evidence

Joflam: Recent Clinical Evidence

The following summary describes findings from studies and clinical trials concerning the investigational drug Joflam (Hypothetamine).


Phase III Evidence for Symptom A

Research on Joflam includes findings from two Phase III randomized, controlled trials (RCTs).

  • These studies evaluated whether the administration of Joflam was associated with a change in the severity of Symptom A. The studies reported a mean reduction of 12% in the study group over eight weeks, relative to the placebo group.
  • Research participants in the study group also showed a lower measurement of Symptom B. The studies included exploration of long-term use.
  • The primary study was designed as an 8-week, double-blind comparison.

Combination Therapy Studies (Joflam + Drug Y)

A key Phase II study evaluated the combination of Joflam and Drug Y. The study reported that the combination group had different Patient-Reported Outcome (PRO) scores compared to the groups receiving either drug alone.

  • The researchers noted that reported change in the combination group occurred at an earlier time point.
  • The study was conducted across 40 clinical centers and followed participants for 12 weeks.

Safety and Adverse Events (Phase I)

Joflam was studied in most adults. During initial research, the following findings were noted:

  • Associated Adverse Events: The most commonly reported events were headache, nausea, and mild fatigue, occurring in less than 10% of participants.
  • Liver Enzyme Association: Two Phase I studies noted that certain dosages were associated with a temporary increase in liver enzymes, especially in people with pre-existing liver conditions.
  • Administration: In the study, the drug was administered with food.

Exploratory Studies (Condition Z)

  • A small observational study in a specialist clinic described the use of Joflam in people with Condition Z. The findings included reports of a numerical change.
  • The current evidence is limited and does not provide sufficient data on this use.

Key Studies & References

  1. Efficacy and Safety of Joflam (Hypothetamine) in Symptom A: A Randomized, Double-Blind, Placebo-Controlled Trial (Trial 1 of 2)
  2. Combined Therapy of Joflam and Drug Y on Patient-Reported Outcomes (PROs): A Phase 2 Multicenter Study

Frequently Asked Questions (FAQ)

Common questions about Joflam (FAQ)


Q: Is Joflam considered a strong medication?

Official information describes the active ingredient, Diclofenac, as a potent inhibitor of prostaglandin synthesis. This strong action at the molecular level is the basis for its documented effects in reducing pain and inflammation. The specific effects on an individual are assessed by a healthcare provider.


Q: Does Joflam cause drowsiness or make it hard to focus?

Official adverse reaction reports list nervous system effects, including headache and dizziness, as commonly documented side effects. Less common effects reported in official documentation can include drowsiness, confusion, and tremor. Adverse effects reported on the nervous system may affect focus.


Q: What common over-the-counter medicines should definitely be avoided while using Joflam?

Regulatory documents describe that the co-administration of Joflam with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is formally not recommended. This combination is associated with an increased risk of serious side effects, particularly affecting the gastrointestinal tract, and is noted in regulatory documentation as not recommended.


Q: Do experts recommend Joflam for long-term use?

Official guidance states that Joflam is to be used for the shortest duration possible and at the lowest effective dose. This is due to the fact that the risk of serious side effects, especially cardiovascular and gastrointestinal events, may increase with the duration of use.


Q: Is Joflam safe for older adults or seniors?

Official labeling notes that older patients are at a greater risk for serious gastrointestinal (GI) events. Because of this increased risk, regulatory authorities note that the lowest possible effective dose is to be considered for this population, with usage determined by a healthcare provider.


Q: Is Joflam available in different strengths?

Yes, official regulatory documents indicate that oral forms of the active ingredient, Diclofenac, are available in multiple strengths. For example, delayed-release tablets are generally available in 25 mg, 50 mg, and 75 mg strengths, with extended-release forms typically available as 100 mg tablets.


Q: Does Joflam have a 'black box warning' in the official documents?

Yes, official U.S. labeling includes a Boxed Warning (often referred to as a black box warning). This warning highlights the serious and potentially life-threatening risks of cardiovascular thrombotic events (such as heart attack and stroke) and severe gastrointestinal adverse events (including bleeding and perforation).


Q: What should I do if I think I'm having a rare side effect from Joflam?

The official label describes symptoms requiring immediate medical attention, such as a severe rash or unexpected swelling. It is noted that these events warrant seeking professional advice without delay. The purpose of the FAQ is to provide descriptive information from official sources, not personalized medical instruction.


Q: Is it better to take Joflam on a full stomach?

Official studies indicate that taking delayed-release tablets with food may slow the rate of absorption and therefore delay the onset of pain relief. However, official labeling describes that the drug may be taken with food, milk, or an antacid if stomach upset occurs.


Q: Does Joflam interact with common beverages like coffee or alcohol?

Official documentation describes that alcohol may increase the risk of serious gastrointestinal problems, such as ulcers and bleeding, when combined with Joflam. The labeling does not contain specific interaction warnings regarding coffee.


Q: Is Joflam safe to use before or after minor surgery?

Joflam is formally contraindicated for treating pain that occurs right after a Coronary Artery Bypass Graft (CABG) surgery. For all other surgical procedures, official caution is advised, and assessment is based on regulatory warnings and precautions.


Q: What is the maximum number of days Joflam is usually recommended for continuous use?

The duration of use varies by the form of the medication. For example, official guidance for injectable forms often limits continuous use to a maximum of two days. For other forms, the overarching principle described in the documentation is the use of the medication for the shortest time period necessary to relieve symptoms.


Q: How quickly can someone expect Joflam to start working?

Official pharmacokinetic data shows that the active substance generally reaches its highest concentration in the blood within approximately two hours of taking delayed-release tablets on an empty stomach. For chronic conditions like arthritis, the full therapeutic effect may take one to two weeks of use.


Q: How long does one dose of Joflam stay active in the body?

The terminal half-life of the active substance in the plasma is approximately two hours. The half-life is a measure of the time it takes for the concentration of the medicine in the body to decrease by half.


Q: Does the time of day matter when taking Joflam?

Official guidance generally calls for the medication to be taken in divided daily doses. For certain specific medical conditions, official documents indicate that a smaller dose may be administered at bedtime to manage symptoms that flare up overnight.


Q: Is Joflam generally considered safe to stop taking suddenly?

Official labeling does not document any safety concerns regarding the abrupt discontinuation of Joflam itself. However, it specifically warns that Joflam cannot be used as a substitute for corticosteroid medicines and that their abrupt stopping is to be avoided.


Q: Do any foods interact with Joflam?

Official studies indicate that while taking the drug with food does not change the total amount absorbed by the body, it may delay the rate of absorption and therefore the onset of pain relief. No specific foods are listed as strictly contraindicated in the labeling.


Q: Is Joflam habit-forming or addictive?

Official regulatory classification confirms that Joflam's active ingredient, Diclofenac, is not classified as a controlled substance. It is not known to be associated with dependency or habit-forming behavior.


Q: Is Joflam a common drug used in hospitals?

The drug is available in parenteral forms (injectable solutions) for intramuscular or intravenous administration. These forms are typically utilized in hospital or acute care settings for the management of acute pain.


Q: Are there specific symptoms that Joflam is not meant to treat?

Joflam is officially indicated for the signs and symptoms of inflammatory conditions like osteoarthritis and rheumatoid arthritis. It is specifically not indicated for managing pain that occurs immediately after a CABG surgery.


Q: Can Joflam affect sleep quality?

Official documents list potential adverse reactions that affect the nervous system. These documented effects include insomnia and dream abnormalities, which may impact sleep quality.


Q: Is there a link between Joflam and changes in mood?

Rare adverse effects reported in the official labeling include changes to mood. These documented effects include depression, anxiety, and psychotic reactions.


Q: Why is Joflam categorized as a prescription-only medicine?

In some jurisdictions, the drug has been classified as prescription-only due to the severity of identified risks, such as the potential for cardiovascular events. This classification indicates the need for a healthcare professional to assess an individual's specific risk factors before the drug is prescribed.


Q: What are the ingredients in Joflam besides the main drug?

Official labeling details the active drug and also lists the inactive ingredients (excipients). These typically include substances used to formulate the product, such as lactose monohydrate, cellulose, dyes, and various coatings.


Q: Is Joflam available as a generic version?

Yes, the active ingredient in Joflam, Diclofenac, is widely available as a generic medication. The generic version is regulated and contains the same active component as the branded product.


Q: Does Joflam interact with birth control pills?

Official regulatory information indicates that Diclofenac will not affect hormonal contraceptives. This means it is not listed as a medication that reduces the effectiveness of birth control pills or other hormonal contraceptive methods.

How should Joflam be stored and disposed of?

Storage and Disposal Requirements

Joflam (Diclofenac) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and excessive heat to maintain its labeled stability. To ensure product integrity, keep the medicine in its original container and ensure the container is tightly closed.

All Diclofenac formulations must be stored out of the reach and sight of children.

For disposal, unused or expired Joflam should not be flushed down a toilet or sink. The preferred method is to use a drug take-back program. If one is unavailable, dispose of the medicine by following the regulatory guidance for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Joflam found in:

A-Z Index: